AIM ImmunoTech Shares Face Investor Scrutiny Amid Financial and Clinical Crosscurrents

AIM ImmunoTech's stock came under significant selling pressure in Friday's trading session. Shares closed at $1.38, marking a decline of 6.12% from the previous close of $1.47. Market activity was volatile, with the price moving between an intraday low of $1.38 and a high of $1.49.

The company's financial runway remains a focal point for market participants. As of the conclusion of Q3 2025, AIM ImmunoTech reported cash and equivalents of approximately $2.4 million. This balance is weighed against a quarterly net loss of $3.3 million, with estimated monthly operating expenditures near $550,000.

Concurrently, the firm is bolstering its intellectual property portfolio. Recent developments include:
* The European Patent Office granting a patent covering the use of lead drug candidate Ampligen for the treatment of Long COVID.
* A separate patent issued in Japan, providing protection until 2039 for novel cancer therapies that combine Ampligen with checkpoint inhibitors.

Should investors sell immediately? Or is it worth buying AIM ImmunoTech?

Clinical Strategy and Recent Commentary

Despite the challenging equity performance, management continues to highlight strategic clinical progress. On December 4th, CEO Thomas K. Equels detailed the clinical and regulatory pathway for Ampligen in a virtual presentation. The company's primary focus is the ongoing DURIPANC study, which is evaluating Ampligen in combination with AstraZeneca's Imfinzi (durvalumab) for the treatment of metastatic pancreatic cancer.

Supporting data from other trials was also emphasized. A completed Phase 2 study in ovarian cancer demonstrated an objective response rate of 50% among 24 evaluable patients. The overarching regulatory strategy involves positioning Ampligen, particularly for pancreatic cancer, as a combination therapy for potential FDA approval.

The recent share price movement suggests investors are carefully balancing the promising clinical milestones and expanded patent protections against the company's persistent losses and constrained financial resources. The market is likely awaiting further data readouts from the DURIPANC trial as the next substantive catalyst.